| Dr Ketan B Patel, MD | |
|
15195 Heathcoat Blvd, Suite 230, Haymarket, VA 20169 | |
| (703) 914-8000 | |
| (703) 642-1876 |
| Full Name | Dr Ketan B Patel |
|---|---|
| Gender | Male |
| Speciality | Interventional Pain Management |
| Experience | 17 Years |
| Location | 15195 Heathcoat Blvd, Haymarket, Virginia |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1881896777 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208VP0014X | Pain Medicine - Interventional Pain Medicine | 0101251492 (Virginia) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Fauquier Hospital | Warrenton, VA | Hospital |
| Novant Health Uva Health Haymarket Medical Center | Haymarket, VA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Inova Health Care Services | 2466351093 | 1725 |
| Physical Medicine Associates Ltd | 4981688835 | 69 |
News Archive
Congressional Budget Office chief Doug Elmendorf dropped a bombshell on his Director's Blog this morning: federal spending on all health care programs will exceed $1 trillion this year. But when he turned to spelling out options for trimming that figure in the years ahead, he offered a limited and not very satisfying menu of choices, all of which involved doing less or charging people more.
Health experts come together today (Thursday) to warn that a new form of superbug that gives bacteria the power to resist virtually all known antibiotics is spreading quickly, posing a global health disaster. It is called New Delhi metallobeta-lactamase, or NDM-1 for short. This enzyme destroys carbapenems, an important group of antibiotics used for difficult infections in hospitals, and has been found in a wide variety of bacterial types. British researchers last August reported that infections involving NDM-1 had been found in patients in Bangladesh, India, Pakistan and Britain.
Adding topotecan to carboplatin plus paclitaxel, the standard treatment for ovarian cancer, does not improve progression-free survival in patients and leads to greater toxicity, according to a study published online October 11 in the Journal of the National Cancer Institute.
Although observational studies have suggested that losartan, a drug used primarily for the treatment of hypertension, may be associated with an increased risk of death among patients with heart failure compared with other medications in the same class of drugs (angiotensin II receptor blockers [ARBs]), an analysis that included nearly 6,500 patients found that overall, use of losartan was not associated with increased all-cause death or cardiovascular death compared with use of the ARB candesartan, according to a study in the April 11 issue of JAMA.
There have been concerns that several SARS-CoV-2 variants have mutations that allow them to evade the immune system. A new study published in the Open Forum Infectious Diseases suggests otherwise. Led by Aaron AR Tobian of Johns Hopkins University School of Medicine, results showed that except for one from the B.1.351 variant, CD8+ T cells showed a broad response to all SARS-CoV-2 variants.
› Verified 6 days ago
| Entity Name | Physical Medicine Associates Ltd |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1003884560 PECOS PAC ID: 4981688835 Enrollment ID: O20071011000434 |
News Archive
Congressional Budget Office chief Doug Elmendorf dropped a bombshell on his Director's Blog this morning: federal spending on all health care programs will exceed $1 trillion this year. But when he turned to spelling out options for trimming that figure in the years ahead, he offered a limited and not very satisfying menu of choices, all of which involved doing less or charging people more.
Health experts come together today (Thursday) to warn that a new form of superbug that gives bacteria the power to resist virtually all known antibiotics is spreading quickly, posing a global health disaster. It is called New Delhi metallobeta-lactamase, or NDM-1 for short. This enzyme destroys carbapenems, an important group of antibiotics used for difficult infections in hospitals, and has been found in a wide variety of bacterial types. British researchers last August reported that infections involving NDM-1 had been found in patients in Bangladesh, India, Pakistan and Britain.
Adding topotecan to carboplatin plus paclitaxel, the standard treatment for ovarian cancer, does not improve progression-free survival in patients and leads to greater toxicity, according to a study published online October 11 in the Journal of the National Cancer Institute.
Although observational studies have suggested that losartan, a drug used primarily for the treatment of hypertension, may be associated with an increased risk of death among patients with heart failure compared with other medications in the same class of drugs (angiotensin II receptor blockers [ARBs]), an analysis that included nearly 6,500 patients found that overall, use of losartan was not associated with increased all-cause death or cardiovascular death compared with use of the ARB candesartan, according to a study in the April 11 issue of JAMA.
There have been concerns that several SARS-CoV-2 variants have mutations that allow them to evade the immune system. A new study published in the Open Forum Infectious Diseases suggests otherwise. Led by Aaron AR Tobian of Johns Hopkins University School of Medicine, results showed that except for one from the B.1.351 variant, CD8+ T cells showed a broad response to all SARS-CoV-2 variants.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Ketan B Patel, MD 11350 Mccormick Road, Executive Plaza 1, Suite 501, Hunt Valley, MD 21031 Ph: (410) 329-1071 | Dr Ketan B Patel, MD 15195 Heathcoat Blvd, Suite 230, Haymarket, VA 20169 Ph: (703) 914-8000 |
News Archive
Congressional Budget Office chief Doug Elmendorf dropped a bombshell on his Director's Blog this morning: federal spending on all health care programs will exceed $1 trillion this year. But when he turned to spelling out options for trimming that figure in the years ahead, he offered a limited and not very satisfying menu of choices, all of which involved doing less or charging people more.
Health experts come together today (Thursday) to warn that a new form of superbug that gives bacteria the power to resist virtually all known antibiotics is spreading quickly, posing a global health disaster. It is called New Delhi metallobeta-lactamase, or NDM-1 for short. This enzyme destroys carbapenems, an important group of antibiotics used for difficult infections in hospitals, and has been found in a wide variety of bacterial types. British researchers last August reported that infections involving NDM-1 had been found in patients in Bangladesh, India, Pakistan and Britain.
Adding topotecan to carboplatin plus paclitaxel, the standard treatment for ovarian cancer, does not improve progression-free survival in patients and leads to greater toxicity, according to a study published online October 11 in the Journal of the National Cancer Institute.
Although observational studies have suggested that losartan, a drug used primarily for the treatment of hypertension, may be associated with an increased risk of death among patients with heart failure compared with other medications in the same class of drugs (angiotensin II receptor blockers [ARBs]), an analysis that included nearly 6,500 patients found that overall, use of losartan was not associated with increased all-cause death or cardiovascular death compared with use of the ARB candesartan, according to a study in the April 11 issue of JAMA.
There have been concerns that several SARS-CoV-2 variants have mutations that allow them to evade the immune system. A new study published in the Open Forum Infectious Diseases suggests otherwise. Led by Aaron AR Tobian of Johns Hopkins University School of Medicine, results showed that except for one from the B.1.351 variant, CD8+ T cells showed a broad response to all SARS-CoV-2 variants.
› Verified 6 days ago